Kevin Bitterman Sells 1,689 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 1,689 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $79.96, for a total value of $135,052.44. Following the completion of the transaction, the director owned 13,427 shares of the company’s stock, valued at $1,073,622.92. The trade was a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

• On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The shares were sold at an average price of $79.98, for a total value of $416,135.94.
• On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The stock was sold at an average price of $80.17, for a total value of $3,941,477.88.
• On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The stock was sold at an average price of $79.95, for a total value of $10,313.55.

Disc Medicine Stock Down 3.1%

Shares of IRON opened at $74.14 on Friday. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The stock has a 50 day simple moving average of $77.92 and a two-hundred day simple moving average of $70.85. The firm has a market cap of $2.85 billion, a P/E ratio of -11.27 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, analysts forecast that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. grew its holdings in Disc Medicine by 103.1% in the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after acquiring an additional 434,000 shares during the last quarter. Engineers Gate Manager LP raised its stake in shares of Disc Medicine by 110.9% during the second quarter. Engineers Gate Manager LP now owns 19,552 shares of the company’s stock valued at $1,430,000 after acquiring an additional 10,282 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Disc Medicine by 139.3% during the second quarter. Squarepoint Ops LLC now owns 75,872 shares of the company’s stock worth $5,549,000 after purchasing an additional 44,163 shares during the period. Arizona State Retirement System grew its stake in shares of Disc Medicine by 2.4% in the second quarter. Arizona State Retirement System now owns 6,844 shares of the company’s stock worth $501,000 after purchasing an additional 160 shares during the last quarter. Finally, Nykredit A S bought a new stake in shares of Disc Medicine in the second quarter worth about $103,000. 83.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IRON has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Disc Medicine in a research note on Tuesday, September 1st. BMO Capital Markets reaffirmed an “outperform” rating on shares of Disc Medicine in a research note on Thursday. Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price objective on shares of Disc Medicine in a report on Monday, August 17th. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Disc Medicine in a research note on Thursday. Finally, Jefferies Financial Group restated a “buy” rating and set a $128.00 target price on shares of Disc Medicine in a report on Thursday. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $109.55.

Trending Headlines about Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Positive Phase 2 RESTORE-PV results: DISC-3405 increased hepcidin, lowered serum iron, maintained hematocrit below 45%, improved symptoms, and substantially reduced phlebotomy needs in patients with polycythemia vera. Among 13 patients completing 26 weeks, average phlebotomies fell from 4.0 to 0.6, while 61.5% remained phlebotomy-free. The drug was generally well tolerated. Disc Medicine Reports Positive Phase 2 RESTORE-PV Data
• Positive Sentiment: Analyst support strengthened: Wedbush reaffirmed its “outperform” rating and raised or maintained a $100 price target, implying meaningful upside from recent trading levels. Other firms, including Morgan Stanley, Cantor Fitzgerald, BMO Capital Markets, and Jefferies, also maintain positive ratings. Benzinga analyst report
• Positive Sentiment: Disc Medicine also highlighted positive data from its RALLY-MF trial of selcodebart in myelofibrosis anemia and expects additional program updates by year-end, supporting the broader pipeline narrative. Disc Medicine Presents RESTORE-PV Results
• Neutral Sentiment: Reported short interest was zero shares, indicating no meaningful evidence of short-covering or bearish short positioning. The figure may reflect incomplete or anomalous data.
• Negative Sentiment: Director Kevin Bitterman sold 1,689 shares for approximately $135,000 under a pre-arranged Rule 10b5-1 plan. While scheduled selling reduces its signal, broader recent insider activity has consisted entirely of sales. Kevin Bitterman Insider Sale
• Negative Sentiment: A law firm announced an investigation into potential securities claims involving allegedly misleading company disclosures. This is only an allegation, but it adds headline and litigation risk. Disc Medicine Investor Investigation
• Negative Sentiment: DISC-3405 remains investigational, and the RESTORE-PV study involved only 40 participants. Investors still face clinical, regulatory, financing, and commercialization risks before the results can translate into revenue.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.